The secret to a healthy life and longevity? Keep inflammation in check!

Premise Biosystems revolutionizes chronic low-grade inflammation detection with advanced cell-based liquid biopsy technology. Read more

Our cutting-edge technology identifies rare abnormal cells associated with inflammation and immune response from a relative small blood volume enabling the detection of the onset of non-communicable diseases such as cancer, heart attack or stroke. Our innovative approach paves the way for earlier interventions and improved patient outcomes.

What Sets Us Apart from Competitors

Premise Biosystems focuses on isolating rare cells without bias from just 10 ml of blood, even when these cells are as scarce as 1 in 50 million normal cells. Our analysis follows the principle of “what is present,” rather than simply relying on biomarker detection based on “if something is there.” This approach maximizes the information we gather about a person’s physiological condition. Our highly informative process enables the detection of subtle abnormalities, offering valuable insights into a patient’s health.

Unrivaled Cell Separation Machine

Our “no-loss-of-information” technology is the first world-wide to enable comprehensive rare cell analysis providing unhindered access to the rare cell populations, leveraged for biomarker discovery and improving systemic disease therapeutics and diagnostics.

Personalize Cancer Solution

We revolutionize a liquid biopsy method to detect cancer signals and systemic inflammation, enabling surveillance of residual cancer in survivors.

Timely Report

We value your time and guarantee prompt delivery of our RARMAX Test Report, enabling you to stay on track and meet your personalize health status.

>89%

Detection Sensitivity in early Invasive Carcinoma

8

Publications

4

Patents

30+

Rare cells Marker Data Collected

Our Professional Leads

Dr. Suparerk Borwornpinyo

CEO and Co-Founder

Dr. Stefan Schreier

Co-Founder

Our Goal in 2030

We aim to build a new healthcare database based on circulating rare cell data with utilizing AI tools to analyze rare cell images and generate detailed patient reports.

With this integration of AI and big data, we aim to enhance diagnostic accuracy and streamline patient care that can save millions of lives.